MCM
CRDF icon

MAI Capital Management’s Cardiff Oncology CRDF Stock Holding History

MAI Capital Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.4K Sell
23,373
-6,131
-21% -$9.73K ﹤0.01% 2025
2026
Q1 		$47.8K Sell
29,504
-22,087
-43% -$45.4K ﹤0.01% 2261
2025
Q4 		$145K Sell
51,591
-14,701
-22% -$34.1K ﹤0.01% 1448
2025
Q3 		$137K Sell
66,292
-438,905
-87% -$1.21M ﹤0.01% 1414
2025
Q2 		$1.59M Sell
505,197
-434,396
-46% -$1.33M 0.01% 546
2025
Q1 		$2.95M Buy
939,593
+23,006
+3% +$91K 0.02% 413
2024
Q4 		$3.98M Buy
916,587
+253,224
+38% +$791K 0.03% 358
2024
Q3 		$1.77M Buy
663,363
+4,569
+0.7% +$10.8K 0.02% 424
2024
Q2 		$1.46M Buy
658,794
+107,670
+20% +$406K 0.01% 488
2024
Q1 		$2.94M Buy
551,124
+171,814
+45% +$457K 0.03% 327
2023
Q4 		$561K Buy
379,310
+154,561
+69% +$187K 0.01% 660
2023
Q3 		$312K Buy
+224,749
New +$379K ﹤0.01% 806

Other funds holding CRDF

LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

MAI Capital Management's CRDF Position: Q2 2026 in Review

MAI Capital Management reduced its Cardiff Oncology (CRDF) stake by 21% in Q2 2026, selling an estimated $9.73K and leaving 23,373 shares worth $30.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

MAI Capital Management first reported a position in CRDF in Q3 2023 and has held it in 12 quarters since. The position peaked at $3.98M in Q4 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

  • MAI Capital Management held 23,373 shares of Cardiff Oncology worth $30.4K as of Q2 2026.
  • MAI Capital Management sold 6,131 Cardiff Oncology shares in Q2 2026, an estimated $9.73K.
  • Cardiff Oncology made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #2025 holding.
  • MAI Capital Management first reported a position in Cardiff Oncology in Q3 2023 and has held it in 12 quarters since.
  • MAI Capital Management's Cardiff Oncology position peaked at $3.98M in Q4 2024.
  • 105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.